Free Trial
NASDAQ:AMRN

Amarin Q1 2025 Earnings Report

Amarin logo
$9.11 -0.25 (-2.67%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$9.38 +0.27 (+2.96%)
As of 04/17/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amarin EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Amarin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Amarin Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, April 30, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Amarin Earnings Headlines

Amarin (NASDAQ:AMRN) Now Covered by Analysts at StockNews.com
The first casualty of the 2025 trade war
The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.
Amarin trading halted, news pending
Amarin confirms effective data for 1-for-20 ADS ratio change
See More Amarin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amarin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amarin and other key companies, straight to your email.

About Amarin

Amarin (NASDAQ:AMRN), a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

View Amarin Profile

More Earnings Resources from MarketBeat